Peptide Science
MOTS-c: a peptide your dog's own mitochondria already make.
What the mouse research shows, and how far it is from a senior dog on the couch.
Most peptides discussed in this section are synthetic compounds given from the outside. MOTS-c is different: it's a naturally occurring, 16-amino-acid peptide that the body already produces, encoded in a short stretch of mitochondrial DNA rather than the cell's main genome.
It was first described in 2015 by researchers studying whether mitochondria — best known for producing cellular energy — also send out their own hormone-like signals. MOTS-c appears to be one of those signals, and researchers have since given it experimentally at higher-than-natural levels to see what it does.
This compound sits in geroscience and metabolic research more than in the repair-and-recovery peptide world discussed elsewhere on this site.
Why mitochondria matter
Mitochondria produce most of the energy a cell uses. Muscle, heart and brain tissue depend on them most heavily, and those are also the systems that most often shape how good an older dog's days are.
What researchers studied
The foundational study identified MOTS-c and tested it in mice: administering it prevented age-related and diet-induced insulin resistance, and prevented diet-induced obesity, primarily by activating a cellular energy-sensing pathway (AMPK) in skeletal muscle.
That is a metabolic and glucose-handling finding, not a mobility, comfort or lifespan finding, and it was conducted entirely in laboratory mice.
Heart research
A separate mouse study induced heart failure through surgically increased pressure on the heart, then gave MOTS-c continuously via an implanted pump. The treated mice showed less cardiac dysfunction and remodeling, along with reduced inflammation and oxidative stress markers in heart tissue.
What we still don't know
Whether exogenous MOTS-c behaves the same way in dogs as in mice — species differences in mitochondrial biology are real and understudied here.
Whether any of this connects to something an owner could observe — energy, stamina, recovery — rather than only laboratory measurements.
Direct canine evidence
None that we are aware of. There is no published canine pharmacokinetic, safety or outcome research on MOTS-c.
Actual studies
- Foundational mouse metabolic studyPubMed PMID 25738459
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
Lee C, Zeng J, Drew BG, et al. Cell Metabolism. 2015;21(3):443-454.
- Study design
- Laboratory study identifying MOTS-c and testing its metabolic effects when administered to mice.
- Population
- Mice; no dogs were studied.
- Intervention
- Exogenous MOTS-c administration in aged and high-fat-diet mouse models.
- What was measured
- Insulin sensitivity, glucose handling, diet-induced obesity and activation of the AMPK energy-sensing pathway in skeletal muscle.
- What the paper reported
- The authors reported that MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and prevented diet-induced obesity in mice.
- Important limitations
- Mouse-only foundational study. Does not address canine physiology, safety or any observable outcome in a pet.
- Controlled mouse heart-failure modelPubMed PMID 36156853
Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice
Zhong P, Peng J, Hu Y, Zhang J, Shen C. Journal of Cellular and Molecular Medicine. 2022;26(21):5369-5378.
- Study design
- Controlled study using surgically induced pressure overload (transverse aortic constriction) in mice, with continuous peptide delivery via an implanted pump, plus supporting cell-culture experiments.
- Population
- Mice; no dogs were studied.
- Intervention
- MOTS-c compared with untreated controls following pressure-overload surgery.
- What was measured
- Cardiac function by echocardiography, cardiac remodeling, inflammatory markers, oxidative stress markers and AMPK pathway activation.
- What the paper reported
- The authors reported that MOTS-c treatment reduced cardiac dysfunction and remodeling and reduced inflammatory and oxidative stress markers in the treated mice.
- Important limitations
- Small mouse study from one research group using a surgically induced disease model. Not naturally occurring heart disease, not conducted in dogs.
Keep reading
BPC-157
ReadCanine preclinical researchSS-31 / Elamipretide
ReadCanine clinical researchBioactive collagen peptides
ReadAnimal / mechanistic researchThymosin Beta-4
ReadDirect canine researchGHK-Cu
ReadAnimal / mechanistic researchKPV
ReadEmerging researchSelank & Semax
ReadEmerging researchThymosin Alpha-1
Read